Bridge Meeting

Course date: 09 February 2021 - 09 February 2021
Location: Online Teams

Nb. Due the COVID-19, the Bridge Meetings will be Online via Teams.
We will send the link around.
The Erasmus MC Bridge-meeting series bridges the gap between Biology, Technology and the Clinic. Each session combines one presentation on biology and one on bioinformatics/technology or a combination of both.
The Bridge meeting is organized under the auspices of MolMed and will be chaired by
Arne IJpma, dept. of Pathology, Unit Bioinformatics, 
Harmen van de Werken, Cancer Computational Biology Center or 
Eskeatnaf Mulugeta, Cell Biology.
The meeting is organized every second Tuesday of the month and will start at 11.00 a.m. and will end around 12.30 p.m.  
After permission is granted by the the speaker, the presentation will be available for download from this intranet site. Please remember that these presentations are only meant within the Erasmus MC. If you wish to share it outside the Erasmus MC, please contact the speaker concerned directly.

We are happy to announce the following two presentations:

  • Pim French - Department of Neurology
    What a diffrence a mutation makes
  • Patrick Kemmeren - princess Maxima Center, Utrecht
    Systems bioinformatics of pediatric cancer

    The Kemmeren group is a computational cancer biology group that uses bioinformatics and systems biology to understand the initiation and progression of childhood cancer as well as aid in the diagnosis and prognosis using cancer genomics. During this presentation, I will give three examples of how we apply our expertise in childhood cancer research and diagnostics. The first example involves using RNA-seq for gene-fusion detection for diagnostic and prognostic purposes. Using this technique, we call all clinically relevant gene-fusion events and have a 40% increased sensitivity. After testing and validation, this is now running as standard-of-care for all children treated at our center. The second example builds upon this concept by investigating the use of WGS and RNA-seq to improve gene-fusion detection. Using a research cohort of 157 pediatric cancer patients, we show that all clinically relevant gene-fusions have genomic support and can decrease the number of false-positive by combining WGS and RNA-seq without the need for manual filtering. In addition, the methodology also generates a list of putative cancer-related gene-fusions and their likely mechanisms for further verification. The last example is aimed at building a map of genetic interactions for childhood cancer. Using two large datasets, we’ve created an overview of co-operating and mutually exclusive interactions for over 3,500 pediatric cancer patients. This map shows that besides synthethic lethality, an important mechanism for developing targeted therapies, other biological mechanisms can explain a large part of the observed interactions. 

Chair: Harmen van de Werken/Arne IJpma/Eskeatnaf Mulugeta

Feel free to forward this announcement among your colleagues and anyone else who may be interested.
The full program of the 2021 Bridge Meetings is available via:
We also have a mailing list for these meetings; let us know if any of your colleagues should be on this mailing list (at:

Click here for the other items